PCI Biotech Holding ASA (OSL:PCIB) Other Current Liabilities: kr5.25 Mil (As of Jun. 2025)


OSL:PCIB PCI Biotech Holding ASA OSL:PCIB
6 GF Score
Price kr0.12
! 1 Warning Sign
View Full Analysis

What is PCI Biotech Holding ASA Other Current Liabilities?

PCI Biotech Holding ASA OSL:PCIB -12.21% 6 Other Current Liabilities is kr5.25 Mil as of Jun. 2025. GuruFocus rates OSL:PCIB with a GF Score™ of 6/100. The stock has 1 warning sign investors should review.

PCI Biotech Holding ASA's other current liabilities for the quarter that ended in Jun. 2025 was kr5.25 Mil.

PCI Biotech Holding ASA's quarterly other current liabilities increased from Jun. 2024 (kr3.49 Mil) to Dec. 2024 (kr4.96 Mil) and increased from Dec. 2024 (kr4.96 Mil) to Jun. 2025 (kr5.25 Mil).

PCI Biotech Holding ASA's annual other current liabilities declined from Dec. 2022 (kr3.59 Mil) to Dec. 2023 (kr3.07 Mil) but then increased from Dec. 2023 (kr3.07 Mil) to Dec. 2024 (kr4.96 Mil).

PCI Biotech Holding ASA Other Current Liabilities Related Terms

PCI Biotech Holding ASA Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for PCI Biotech Holding ASA's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PCI Biotech Holding ASA Other Current Liabilities Chart

PCI Biotech Holding ASA Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.88 14.82 3.59 3.07 4.96

PCI Biotech Holding ASA Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.61 3.07 3.49 4.96 5.25
OSL:PCIB
6GF Score
PCI Biotech Holding ASA OSL:PCIB
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PCI Biotech Holding ASA Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of kr5.25 Mil mean?
PCI Biotech Holding ASA (OSL:PCIB) has a Other Current Liabilities of kr5.25 Mil as of Jun. 2025. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on PCI Biotech Holding ASA.
Is PCI Biotech Holding ASA's Other Current Liabilities too high?
PCI Biotech Holding ASA's current Other Current Liabilities is kr5.25 Mil. Overall, PCI Biotech Holding ASA has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does PCI Biotech Holding ASA's Other Current Liabilities compare to VRTX and REGN?
PCI Biotech Holding ASA's Other Current Liabilities of kr5.25 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on PCI Biotech Holding ASA. PCI Biotech Holding ASA's current Other Current Liabilities is kr5.25 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PCI Biotech Holding ASA stock overvalued right now?
PCI Biotech Holding ASA (OSL:PCIB) has a current Other Current Liabilities of kr5.25 Mil. The current Other Current Liabilities is kr5.25 Mil. PCI Biotech Holding ASA's overall GF Score™ is 6/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For PCI Biotech Holding ASA (OSL:PCIB), the current Other Current Liabilities is kr5.25 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PCI Biotech Holding ASA Business Description

Address Ullernchausseen 64, Oslo, NOR, N-0379
PCI Biotech Holding ASA is a biopharmaceutical company focused on developing and commercializing cancer therapies using its photochemical internalization (PCI) technology platform. The PCI technology utilizes light to trigger the release of compounds from within cellular compartments. The company applies PCI to three different approaches for cancer treatment: fimaCHEM: Enhancing chemotherapeutic drugs for localized cancer treatment. fimaVACC: Inducing T-cell responses for therapeutic cancer vaccination. fimaNAc: Delivering nucleic acid therapeutics. The key product candidate is fimaporfin (Amphinex), a photosensitizer that can unlock intracellular compartments where active compounds are trapped. The company's sole operating segment is research and development.
6GF Score

Get the complete analysis for OSL:PCIB

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.12
Price